Form 4: GlucoTrack Director Erin Carter Reports Securities Transactions

Sentiment:

SEC Form 4 Filing 31 March 2025 7:52 AM

Director Erin Carter reports multiple transactions involving GlucoTrack, Inc. common stock and convertible promissory notes.

Capital raiseThe convertible promissory note converts upon a Qualified Financing, defined as the issuance and sale of capital stock resulting in gross proceeds of at least $500,000 to the Company.The note converted on November 14, 2024, following a Qualified Financing.

Summary

Erin Carter, a director of GlucoTrack, Inc., filed a Form 4 detailing several transactions.
On December 31, 2023, Carter acquired 903 shares of common stock.
On April 8, 2024, Carter acquired 458 shares of common stock.
On November 14, 2024, Carter acquired 2,078 shares of common stock through the conversion of a promissory note at $31.20 per share.
On March 12, 2025, Carter acquired 40,297 shares of common stock through the cashless exercise of Series B Common Warrants.
On March 26, 2025, Carter acquired 1,896 shares of common stock.
Carter also holds Series A and Series B common warrants.
Reverse stock splits occurred on May 17, 2024 (1-for-5) and February 25, 2025 (1-for-20); all figures reflect these splits.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard disclosures for company insiders and provide transparency into their transactions, which can be indicative of their confidence in the company's prospects.

Stakeholder Impact

Shareholders may use this information to assess insider confidence and make informed investment decisions.

Key Dates

Date	Description
12/31/2023	Acquisition of 903 shares of common stock.
04/08/2024	Acquisition of 458 shares of common stock.
05/17/2024	1-for-5 reverse stock split implemented.
07/18/2024	Purchase of a $50,000 convertible promissory note.
11/14/2024	Conversion of promissory note into common stock and issuance of Series A and B warrants.
02/25/2025	1-for-20 reverse stock split implemented.
03/06/2025	Date of Power of Attorney execution.
03/12/2025	Cashless exercise of Series B Common Warrants.
03/26/2025	Acquisition of 1,896 shares of common stock.
03/31/2025	Date of Form 4 signature.

Keywords

Form 4, GlucoTrack, Director, Erin Carter, Securities, Common Stock, Convertible Note, Warrants, Reverse Stock Split, Qualified Financing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.